Metraipolis › archive › dc_cdcc1e19f0af

Tumor immune microenvironment permissive to metastatic progression of ING4-deficient breast cancer — Europe PMC PMID:38968186

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/38968186
DOI
10.1371/journal.pone.0304194
License (as archived)
CC0-1.0
Archived
2026-10-06T17:10:10.842Z
SHA-256 of the archived text
723c91d59cfcef65d9c9f6ae6ed9b0f533bbc93b42dae5eb3e1ccc168481db20
Stable URL of this page
https://metraipolis.com/documento/dc_cdcc1e19f0af

How to cite

Tumor immune microenvironment permissive to metastatic progression of ING4-deficient breast cancer — Europe PMC PMID:38968186 — Europe PMC (en), https://europepmc.org/article/MED/38968186 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_cdcc1e19f0af (Metraipolis archive dc_cdcc1e19f0af, sha256 723c91d59cfcef65d9c9f6ae6ed9b0f533bbc93b42dae5eb3e1ccc168481db20)
BibTeX
@misc{dccdcc1e19f0af,
  title = {Tumor immune microenvironment permissive to metastatic progression of ING4-deficient breast cancer — Europe PMC PMID:38968186},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/38968186},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_cdcc1e19f0af; sha256 723c91d59cfcef65d9c9f6ae6ed9b0f533bbc93b42dae5eb3e1ccc168481db20},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38968186. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Deficiencies in the ING4 tumor suppressor are associated with advanced stage tumors and poor patient survival in cancer. ING4 was shown to inhibit NF-kB in several cancers. As NF-kB is a key mediator of immune response, the ING4/NF-kB axis is likely to manifest in tumor-immune modulation but has not been investigated. To characterize the tumor immune microenvironment associated with ING4-deficient tumors, three approaches were employed in this study: First, tissue microarrays composed of 246 primary breast tumors including 97 ING4-deficient tumors were evaluated for the presence of selective immune markers, CD68, CD4, CD8, and PD-1, using immunohistochemical staining. Second, an immune-competent mouse model of ING4-deficient breast cancer was devised utilizing CRISPR-mediated deletion of Ing4 in a Tp53 deletion-derived mammary tumor cell line; mammary tumors were evaluated for immune markers using flow cytometry. Lastly, the METABRIC gene expression dataset was evaluated for patient survival related to the immune markers associated with Ing4-deleted tumors. The results showed that CD68, CD4, CD8, or PD-1, was not significantly associated with ING4-deficient breast tumors, indicating no enrichment of macrophages, T cells, or exhausted T cell types. In mice, Ing4-deleted mammary tumors had a growth rate comparable to Ing4-intact tumors but showed increased tumor penetrance and metastasis. Immune marker analyses of Ing4-deleted tumors revealed a significant increase in tumor-associated macrophages (Gr-1loCD11b+F4/80+) and a decrease in granzyme B-positive (GzmB+) CD4+ T cells, indicating a suppressive and/or less tumoricidal immune microenvironment. The METABRIC data analyses showed that low expression of GZMB was significantly associated with poor patient survival, as was ING4-low expression, in the basal subtype of breast cancer. Patients with GZMB-low/ING4-low tumors had the worst survival outcomes (HR = 2.80, 95% CI 1.36-5.75, p = 0.0004), supportive of the idea that the GZMB-low immune environment contributes to ING4-deficient tumor progression. Collectively, the study results demonstrate that ING4-deficient tumors harbor a microenvironment that contributes to immune evasion and metastasis.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2024 (prima pubblicazione 2024-07-05).
Identificativi: PMID 38968186 · PMCID PMC11226078 · DOI 10.1371/journal.pone.0304194.
Descrittori MeSH principali: Breast Neoplasms; Cell Cycle Proteins; Homeodomain Proteins; Tumor Suppressor Proteins; Tumor Microenvironment.
Pagina: https://europepmc.org/article/MED/38968186 — https://doi.org/10.1371/journal.pone.0304194. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T15:36:02.980Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.